一个新的 m6A 甲基化相关基因标志物，用于预测膀胱癌患者的预后。

A new m6A methylation-related gene signature for prognostic value in patient with urothelial carcinoma of the bladder.

机构信息

Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P.R. China.

Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, P.R. China.

出版信息

Biosci Rep. 2021 Apr 30;41(4). doi: 10.1042/BSR20204456.

BACKGROUND

Bladder cancer (BC) is one of the most common malignant urological cancer in the world. Because of its characteristic of easy-recurrence and muscle-invasive, advances in our genetic understanding of bladder cancer should be translated into prognostic indicators.

METHODS

We investigated 16 m6A RNA methylation regulators from The Cancer Genome Atlas (TCGA) database and The Human Protein Atlas (HPA) database. The expression profile, clinical application as well as prognostic value of these genes in UC were investigated. Moreover, we further explored the correlation between RNA methylation genes and biological functions, pathways and immune status.

RESULTS

Five m6A-related genes (HNRNPC, YTHDF2, YTHDF1, HNRNPA2B1, METTL3) up-regulated in UC tissues, while three regulators (ZC3H13, METTL16, FTO) down-regulated in UC. FTO and YTHDF2 show biomarker potential for the prognosis of UC patients. In addition, these identified genes may related with essential functions and core molecular pathways.

CONCLUSIONS

Our research shows that two m6A RNA methylation regulators can serve as reliable prognostic biomarkers of UC, which might be exerted as potential targets of therapeutic strategies.

背景

膀胱癌（BC）是世界上最常见的恶性泌尿系统癌症之一。由于其易复发和肌肉浸润的特点，我们对膀胱癌的遗传理解的进展应该转化为预后指标。

方法

我们从癌症基因组图谱（TCGA）数据库和人类蛋白质图谱（HPA）数据库中研究了 16 个 m6A RNA 甲基化调节剂。研究了这些基因在 UC 中的表达谱、临床应用和预后价值。此外，我们还进一步探讨了 RNA 甲基化基因与生物学功能、途径和免疫状态的相关性。

结果

在 UC 组织中上调了五个 m6A 相关基因（HNRNPC、YTHDF2、YTHDF1、HNRNPA2B1、METTL3），而在 UC 中下调了三个调节剂（ZC3H13、METTL16、FTO）。FTO 和 YTHDF2 显示出对 UC 患者预后的潜在生物标志物特征。此外，这些鉴定的基因可能与基本功能和核心分子途径有关。